司美格鲁肽是“神奇”药物吗？减重38斤的书作者分享其经验

Core Viewpoint - The article discusses the impact and implications of GLP-1 medications, particularly focusing on the experiences of Johann Hari with Ozempic and Wegovy, highlighting both the benefits and potential risks associated with their use [4][8][14]. Group 1: Personal Experience with GLP-1 Medications - Johann Hari initially weighed 203 pounds (approximately 92 kg) with a body fat percentage of 32% and was prescribed Ozempic for weight loss, which he found effective in reducing his appetite and achieving a weight loss of 42 pounds (about 19 kg) [8]. - The medications are described as a large-scale experiment for many individuals, as they address the obesity epidemic exacerbated by processed foods, restoring a sense of satiety [8][16]. - Despite the weight loss and physical benefits, Hari experienced psychological challenges, feeling worse emotionally due to the inability to use food as a comfort mechanism [10][12]. Group 2: Risks and Side Effects - The article outlines several potential risks associated with Ozempic, including a 50-75% increased risk of thyroid cancer, a 9-fold increase in the likelihood of pancreatitis, and a 30% muscle loss risk that could lead to sarcopenia in older age [13]. - There are also concerns about the psychological effects, including depression and suicidal tendencies, as well as the possibility of weight regain after discontinuation of the medication [13][14]. - The side effects experienced by Hari included mild discomfort and an unusual side effect of increased heart rate, which contributed to anxiety [12][13]. Group 3: Societal Implications - The high cost of Ozempic has led to shortages for diabetic patients who are forced to switch to insulin, highlighting a growing divide in access to these medications [17]. - By 2030, it is projected that 50% of Western populations may be using such medications, while poorer populations remain trapped in a cycle of obesity and related health issues [17].